Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Condition:   Hidradenitis Suppurativa Interventions:   Drug: Deucravacitinib;   Drug: Placebo Sponsors:   Beth Israel Deaconess Medical Center;   Bristol-Myers Squibb Not yet recruiting

Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials